Mr Nunn has relevant sector knowledge from decades spent in US healthcare portfolio management, financial analysis and other board roles. Mr Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Prior to joining NEA, he served as a partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. Mr Nunn served on the board of directors of Dermira, a publicly-held biopharmaceutical company focused on dermatology, from 2011 until the recent acquisition by Eli Lilly in February 2020. Mr Nunn currently serves on the board of directors of Trevena, Inc., a publicly-held biotechnology company focused on CNS, Addex Therapeutics Ltd., a publicly held biopharmaceutical company focused on allosteric modulators for neurological disorders, and Regulus Therapeutics Inc. a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. From 2009 to May 2015, Mr Nunn served on the board of directors of Hyperion Therapeutics, Inc. and from 2008 to February 2016, Mr Nunn served on the board of directors of TriVascular Technologies, Inc.